New and Novel Therapies for Gynecologic Cancers
- PMID: 30876683
- DOI: 10.1016/j.soncn.2019.02.009
New and Novel Therapies for Gynecologic Cancers
Abstract
Objective: To review recent therapies approved by the US Food and Drug Administration for the treatment of gynecologic malignancies.
Data sources: PubMed, FDA.gov, ASCO.org.
Conclusion: The landscape for treating gynecologic malignancies is rapidly changing. Maintenance therapy now exists for women with advanced ovarian cancer after completing chemotherapy for both newly diagnosed and platinum-sensitive recurrent ovarian cancer. Anti-angiogenic therapy has many applications in gynecologic malignancies. Immunotherapy can be used in certain situations for women with gynecologic malignancies.
Implications for nursing practice: Biologic agents and immunotherapy have distinct side-effect profiles that nurses need to be aware of to optimize patient care and outcomes.
Keywords: bevacizumab; cervical cancer; endometrial cancer; ovarian cancer; parp inhibitors; pembrolizumab.
Copyright © 2019 Elsevier Inc. All rights reserved.
Similar articles
-
Current Systemic Treatment Landscape of Advanced Gynecologic Malignancies.Target Oncol. 2019 Jun;14(3):269-283. doi: 10.1007/s11523-019-00641-9. Target Oncol. 2019. PMID: 31069647 Review.
-
Metastatic gynecologic malignancies: advances in treatment and management.Clin Exp Metastasis. 2018 Aug;35(5-6):521-533. doi: 10.1007/s10585-018-9889-7. Epub 2018 Jun 21. Clin Exp Metastasis. 2018. PMID: 29931499 Review.
-
Advancing Drug Development in Gynecologic Malignancies.Clin Cancer Res. 2019 Aug 15;25(16):4874-4880. doi: 10.1158/1078-0432.CCR-19-0619. Epub 2019 May 24. Clin Cancer Res. 2019. PMID: 31126961 Free PMC article. Review.
-
Clinical applications of antibody drug conjugates for gynecologic malignancies: Review of available medicines and emerging therapeutics.Gynecol Oncol. 2025 Apr;195:180-191. doi: 10.1016/j.ygyno.2025.03.013. Epub 2025 Mar 25. Gynecol Oncol. 2025. PMID: 40139025 Review.
-
The evolving landscape of antibody-drug conjugates in gynecologic cancers.Cancer Treat Rev. 2023 May;116:102546. doi: 10.1016/j.ctrv.2023.102546. Epub 2023 Mar 20. Cancer Treat Rev. 2023. PMID: 37023499 Review.
Cited by
-
Paclitaxel, Carboplatin, and Bevacizumab in Advanced Cervical Cancer: A Treatment Response and Safety Analysis.Dose Response. 2020 Jul 29;18(3):1559325820941351. doi: 10.1177/1559325820941351. eCollection 2020 Jul-Sep. Dose Response. 2020. PMID: 32774193 Free PMC article.
-
TGF-β signaling proteins and CYP24A1 may serve as surrogate markers for progesterone calcitriol treatment in ovarian and endometrial cancers of different histological types.Transl Cancer Res. 2019 Aug;8(4):1423-1437. doi: 10.21037/tcr.2019.07.36. Transl Cancer Res. 2019. Retraction in: Transl Cancer Res. 2025 May 30;14(5):3270. doi: 10.21037/tcr-2025b-5. PMID: 35116885 Free PMC article. Retracted.
-
Adipose-derived mesenchymal stem cells induced PAX8 promotes ovarian cancer cell growth by stabilizing TAZ protein.J Cell Mol Med. 2021 May;25(9):4434-4443. doi: 10.1111/jcmm.16511. Epub 2021 Apr 8. J Cell Mol Med. 2021. PMID: 33830648 Free PMC article.
-
Gene polymorphism and prediction of toxicity to platinum-based chemotherapy in patients with gynecologic cancer.Clin Transl Sci. 2023 Dec;16(12):2519-2529. doi: 10.1111/cts.13642. Epub 2023 Nov 27. Clin Transl Sci. 2023. PMID: 38013655 Free PMC article.
-
Adipose-Derived Mesenchymal Stem Cells Enhance Ovarian Cancer Growth and Metastasis by Increasing Thymosin Beta 4X-Linked Expression.Stem Cells Int. 2019 Oct 20;2019:9037197. doi: 10.1155/2019/9037197. eCollection 2019. Stem Cells Int. 2019. PMID: 31781249 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
